IDEXX Laboratories, Inc. IDXX
- Market cap
- $40.2B
- P/E
- 36.2×
Follow IDXX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.48 | 113.92 | 157.53 | 176.11 | 168.65 | 455.23 | 317.06 | 372.50 | 398.50 | 356.14 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 121.77 | 173.01 | 256.22 | 294.57 | 503.83 | 706.95 | 656.31 | 568.30 | 583.39 | 769.98 |
High Price
|
|||
| 7,365 | 7,600 | 8,377 | 9,200 | 9,300 | 10,350 | 10,780 | 11,000 | 11,000 | 11,000 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 1,775 | 1,969 | 2,213 | 2,407 | 2,707 | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 |
Revenue
|
|||
| 54.94% | 55.73% | 56.10% | 56.73% | 58.04% | 58.76% | 59.52% | 59.82% | 61.04% | 61.80% |
Gross Margin
|
|||
| 322 | 381 | 458 | 522 | 662 | 903 | 860 | 1,061 | 1,110 | 1,324 |
EBT
|
|||
| 18.13% | 19.35% | 20.68% | 21.70% | 24.46% | 28.07% | 25.54% | 28.99% | 28.48% | 30.77% |
EBT Margin
|
|||
| 222 | 263 | 377 | 428 | 582 | 745 | 679 | 845 | 888 | 1,059 |
Net Income
|
|||
| 79 | 83 | 83 | 88 | 96 | 105 | 112 | 115 | 130 | 145 |
Depreciation
|
|||
| 19.79 | 22.43 | 25.48 | 27.95 | 31.72 | 37.74 | 40.27 | 44.07 | 47.26 | 53.51 |
Revenue/Sh
|
|||
| 2.47 | 3.00 | 4.34 | 4.97 | 6.82 | 8.74 | 8.12 | 10.17 | 10.77 | 13.17 |
Earnings/Sh
|
|||
| 3.78 | 4.25 | 4.61 | 5.33 | 7.59 | 8.87 | 6.49 | 10.91 | 11.27 | 14.69 |
Cash Flow/Sh
|
|||
| (0.72) | (0.87) | (1.42) | (1.80) | (1.26) | (1.40) | (1.90) | (1.61) | (1.59) | (1.72) |
Capex/Sh
|
|||
| 3.06 | 3.38 | 3.19 | 3.53 | 6.33 | 7.46 | 4.59 | 9.30 | 9.68 | 12.98 |
Free CF/Sh
|
|||
| (1.21) | (0.61) | (0.11) | 2.07 | 7.41 | 8.10 | 7.28 | 17.87 | 19.34 | 19.96 |
Book Value/Sh
|
|||
| 90 | 88 | 87 | 86 | 85 | 85 | 84 | 83 | 82 | 80 |
Shares
|
|||
| 47.42 | 52.60 | 42.96 | 52.65 | 73.40 | 75.34 | 50.00 | 53.85 | 38.39 | 51.33 |
PE Ratio
|
|||
| 5.94 | 7.03 | 7.30 | 9.34 | 15.76 | 17.45 | 10.08 | 12.43 | 8.75 | 12.64 |
PS Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 126.46 | 67.42 | 81.31 | 55.77 | 30.65 | 21.37 | 33.89 |
PB Ratio
|
|||
| 6.06 | 7.10 | 7.52 | 9.72 | 15.95 | 17.67 | 10.28 | 12.49 | 8.83 | 12.71 |
EV/Sales
|
|||
| 39.23 | 47.16 | 60.54 | 78.85 | 79.91 | 89.94 | 90.09 | 59.95 | 47.74 | 57.16 |
EV/FCF
|
|||
| 339 | 373 | 400 | 459 | 648 | 756 | 543 | 907 | 929 | 1,182 |
Op' Cash Flow
|
|||
| (65) | (77) | (123) | (155) | (108) | (120) | (159) | (134) | (131) | (138) |
Capex
|
|||
| 274 | 297 | 277 | 304 | 540 | 636 | 384 | 773 | 798 | 1,044 |
FCF
|
|||
| (89) | (33) | (116) | (46) | 480 | 192 | (134) | 544 | 332 | 265 |
Working Cap'
|
|||
| 1,204 | 1,261 | 1,000 | 1,003 | 908 | 850 | 769 | 698 | 618 | 450 |
Total Debt
|
|||
| 812 | 789 | 877 | 913 | 525 | 706 | 657 | 244 | 329 | 270 |
Net Debt
|
|||
| (108) | (54) | (9) | 178 | 633 | 690 | 609 | 1,485 | 1,595 | 1,605 |
Sh' Equity
|
|||
| 14.77% | 16.22% | 23.20% | 25.39% | 28.19% | 31.48% | 26.20% | 28.14% | 27.10% | 31.89% |
ROA
|
|||
| 31.09% | 35.11% | 35.41% | 31.69% | 37.51% | 41.74% | 44.39% | 39.67% | 36.64% | 45.33% |
ROIC
|
|||
| (231.05%) | (324.76%) | (1,195.50%) | 507.40% | 143.54% | 112.62% | 104.58% | 80.74% | 57.66% | 66.20% |
ROE
|
|||
IDEXX Laboratories, Inc. (IDXX) key facts
- IDEXX Laboratories, Inc. (IDXX) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Net income was $1.1 billion, or $13.17 per share (basic), a net margin of 24.6%.
- As of September 25, 2026, IDXX traded at $519.26, a market capitalization of $40.2 billion.
- At that price the stock trades at 36.2× trailing-twelve-month earnings and 9.0× sales.
- Return on equity was 66.2% and debt-to-equity 0.28.
IDEXX Laboratories, Inc. (IDXX) Latest News
23 Sep
IDEXX Laboratories is strengthening its Companion Animal Group through recurring revenue growth, broader diagnostic offerings and expanding software adoption. In 2Q2026, CAG Diagnostics posted 10.3% organic recurring revenue growth, with about 4% global net price improvement and rising instrument placements. InVue Dx installations surpassed 9,000 after 1,602 placements in the quarter. Cloud-based software platforms (PIMS) and Vello active users posted double-digit growth, with ezyVet-linked wellness bloodwork rising. International CAG Diagnostics grew nearly 12% organically, driven by new customers and higher utilization, with four international expansions planned in 2026. Cancer Dx has expanded globally and DR radiography placements continued a multi-quarter record run. Headwinds include foreign exchange exposure and a continued decline in U.S. veterinary visits, which could cap growth despite strong fundamentals. Zacks ranks IDXX as Hold. Currency headwinds and waning U.S. visits temper otherwise strong CAG and software growth.
20 Sep
IDEXX Laboratories highlights its diagnostic pipeline and reaffirms long-term growth targets. Diagnostic pipeline updates and growth target reaffirmation point to moderate effects on innovation and market positioning.
19 Sep
IDEXX Laboratories is deploying an AI scribe tool to drive higher sales of its pet diagnostics products. AI scribe targets improved sales efficiency in core veterinary diagnostics operations.
17 Sep
IDEXX Laboratories acquires CoVet, resulting in gains for its stock. Acquisition of CoVet marks a major strategic expansion with potential to significantly shift company trajectory.
IDEXX Laboratories (IDXX) stock may trade 29% below fair value as diagnostics growth remains central to its outlook. Valuation assessment pointing to 29% undervaluation can moderately sway IDXX investor sentiment and near-term performance.
IDEXX Laboratories expands its zoonosis testing menu, raising questions on whether this development alters the investment case for the company. Expanded zoonosis testing menu may moderately affect competitive positioning in diagnostics without fundamentally shifting company trajectory.
16 Sep
IDEXX Laboratories, Inc. acquired CoVetAI to advance veterinary workflow intelligence. Acquisition of CoVetAI is a major strategic move in veterinary diagnostics likely to significantly alter IDEXX trajectory and investor sentiment.
20 Aug
IDEXX Laboratories raised its 2026 EPS outlook citing diagnostic growth and margin expansion. Raised 2026 EPS outlook signals stronger expected profitability from core diagnostics business.
14 Aug
IDEXX Laboratories targets a $45B pet diagnostics market opportunity via AI tools and cancer tests. AI and cancer test initiatives target major expansion in core pet diagnostics operations.
12 Aug
IDEXX Laboratories posts strong Q2 2026 results and releases a new cardiac test that may shift perceptions of the company's growth prospects. Strong quarterly results plus a new product launch moderately affect revenue outlook and competitive stance without guaranteeing fundamental change.
11 Aug
IDEXX Laboratories introduces the first and only dual-species point-of-care NT-proBNP test for cardiac disease detection on its Catalyst platform. First dual-species point-of-care cardiac test expands Catalyst platform into major new disease category with no direct competitors.
IDEXX Laboratories, Inc. (IDXX) held its Q2 2026 earnings call. Earnings call delivers quarterly results and guidance that can shift near-term stock sentiment and analyst views.
6 Aug
IDEXX Laboratories (IDXX) shows strong growth prospects making it a buy for growth investors. Growth outlook for IDXX is positioned to lift investor sentiment and near-term stock performance.
4 Aug
IDXX beat Q2 earnings and revenue estimates, raised its 2026 EPS outlook, and its stock rose in pre-market trading. Q2 beat combined with higher 2026 EPS guidance signals stronger profitability and lifts near-term valuation.
IDEXX Laboratories announced its second quarter results. Quarterly earnings releases typically drive notable stock price shifts and investor reassessment of financial trajectory.
IDEXX Laboratories, Inc. presented Q2 2026 financial results and outlook during its earnings call, covering revenue, earnings, segment performance, and forward guidance. Quarterly results and guidance typically produce moderate effects on near-term valuation and operational expectations.
IDEXX Laboratories reported strong revenue growth during its Q2 2026 earnings call. Q2 2026 revenue growth directly influences near-term financial results and investor views on IDEXX Laboratories.
IDEXX Laboratories Q2 earnings call highlighted financial results, revenue growth, operational updates, and outlook for the veterinary diagnostics business. Quarterly earnings details can shift near-term investor views and valuation but rarely alter long-term company trajectory.
IDEXX Laboratories reported Q2 earnings with focus on key metrics reflecting operational and financial results. Q2 earnings release with key metrics can moderately shift investor views on financial performance.
IDEXX Laboratories beat earnings expectations and raised its full-year outlook, prompting its shares to climb. Earnings beat with improved outlook lifts near-term stock performance and sentiment for IDEXX Laboratories without altering long-term trajectory.
IDEXX Laboratories reported Q2 earnings and revenues that topped analyst estimates. Q2 earnings beat offers moderate positive signal for near-term sentiment and performance.
22 Jun
IDEXX Laboratories plans a minor product upgrade expected to deliver substantial operational benefits and improved outcomes for its core veterinary diagnostics customers. Small upgrade may improve customer workflows and sentiment but remains incremental rather than transformative for overall financial trajectory.
3 Jun
IDEXX Laboratories expands parasite testing products, connecting to zoonotic disease risks and triggering valuation debates for the company. Parasite test expansion strengthens IDEXX position in zoonotic diagnostics but pairs with valuation debate that caps near-term trajectory shifts.
27 May
IDEXX Laboratories integrates an early kidney disease detector into its most popular test profile. Integration of kidney disease detection into core test profiles strengthens IDEXX diagnostic offerings and competitive positioning.
20 May
IDEXX Laboratories enhances Catalyst panels with SDMA technology for improved kidney disease detection in pets, prompting evaluation by long-term diagnostics investors on strategic positioning and growth prospects. SDMA-enhanced panels offer incremental diagnostic improvements that may support IDEXX market share in veterinary testing without transforming overall company trajectory.
19 May
IDEXX Laboratories integrates SDMA testing into its most common Catalyst chemistry profiles, expanding routine access to this kidney function biomarker for veterinary practices. Integration improves test accessibility and supports wider SDMA adoption in core diagnostic workflows.
7 May
Analysts updated estimates for IDEXX Laboratories (IDXX) following its first-quarter report, reflecting brokers' views on the company's performance. Post-Q1 analyst estimates moderately influence financial performance expectations and investor sentiment for IDXX.
5 May
IDEXX Laboratories Q1 earnings call highlights strong revenue growth driven by companion animal group, robust international expansion, and reaffirmed full-year guidance amid positive outlook. Q1 earnings highlights detail financial results, growth metrics, and guidance that significantly shape investor sentiment and stock trajectory.
IDEXX Laboratories, Inc. Q1 2026 earnings call summary covers financial results, operational performance, and forward guidance for the veterinary diagnostics leader. Quarterly earnings summaries reveal revenue growth, EPS beats, and raised guidance that drive substantial stock price movements and investor confidence.
IDEXX Laboratories (IDXX) Q1 2026 earnings call transcript released, detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance, strategic updates, and outlook that significantly shape investor sentiment and stock trajectory.